Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 139 for “"Cancer Cachexia"”.
-
Role of Sex Differences on Cancer Cachexia Progression and Fibrosis during Cancer Cachexia Development
Cancer cachexia is a multifactorial wasting syndrome characterized by losses in bodymass >5% and occurs in approximately 80% of all cancer patients. Chronic inflammation and fibrosis play roles in cancer cachexia and a greater understanding of these contributing pathways to this pathology will pave …
-
Phenotypes and genetic markers of cancer cachexia
Cancer cachexia is a chronic wasting syndrome characterised by loss of weight, composed principally of muscle and fat. Patients with advanced cachexia demonstrate loss of appetite, early satiety, severe weight loss, weakness, anaemia and fluid retention. Affected individuals are also likely to …
-
Insulin, metabolism and cancer cachexia in the rat
Bibliography: leaf 152-167.
-
Mechanism of muscle protein degradation in Cancer Cachexia
… weight 24 KDa (p24) was purified both from the cachexia-inducing MAC 16 tumour and the urine of cachectic cancer patients by a combination of ammonium sulphate precipitation and affinity chromatography using a monoclonal antibody developed against the murine material. Administration of p24 to …
-
Purification and characterisation of two cancer cachexia factors
Cachexia is a wasting phenomenon that often accompanies malignant disease. Its manifestation is associated with shortened survival and reduced responsiveness to anti-tumour therapy and as yet there is no established, effective amelioratory treatment. The MAC 16 model of cancer cachexia has been …
-
RNA Sequencing in the Development of Cancer-Cachexia
Introduction: Cancer is a major public health problem in the U.S. and the world. In 2013 there were an estimated 1,660,290 new cases of cancer in the U.S. Cancer-Cachexia (CC) is a common effect of many cancers, and is directly responsible for 20-40% of cancer-related deaths. The mechanisms that …
-
Musculoskeletal Effects of Oncostatin M in Pancreatic Cancer Cachexia
… (PDAC) is the third leading cause of cancerrelated deaths with a five-year survival rate of 11%. PDAC tumors are characterized by a dense desmoplastic stromal microenvironment, mediated in part through local cytokine production. PDAC tumors also elicit a systemic inflammatory response …
-
Cancer Heterogeneity and Mitochondrial-Targeted Therapies in Cancer Cachexia
Cancer Cachexia (CC) is a multifactorial and complex syndrome affecting up to 80% of cancer patients and contributing to approximately 40% of cancer-related deaths. Given its relationship with patients' quality of life and prognosis, there has been increasing emphasis on understanding the …
-
Targeting cancer cachexia via inhibition of soluble epoxide hydrolase
Cancer cachexia is an incapacitating condition characterized by progressive muscle wasting and hyperinflammation, for which there are currently no effective therapeutic remedies available. The underlying mechanisms of cachexia remain poorly understood. However, studies now understand the …
-
The role of pro-resolving mediators in cancer cachexia
Cancer cachexia is a complex and multifactorial syndrome characterized by persistent inflammation, leading to severe muscle wasting, weight loss, and metabolic dysfunction. Conventional anti-inflammatory approaches have exhibited limited efficacy in effectively managing patient outcomes, …
-
Mechanism of protein catobolism in skeletal muscle during cancer cachexia
Cancer cachexia is characterised by selective depletion of skeletal muscle protein reserves. The ubiquitin-proteasome proteolytic pathway has been shown to be responsible for muscle wasting in a range of cachectic conditions including cancer cachexia. To establish the importance of this pathway in …
-
Cellular signalling pathways involved in muscle atrophy in cancer cachexia
Cancer cachexia encompases severe weight loss, characterised by the debilitating atrophy of adipose and skeletal muscle mass. Skeletal muscle proteolysis in cancer cachexia is mediated by a sulphated glycoprotein with a relative molecular mass of 24kDa, termed Proteolysis-Inducing Factor (PIF). PIF …
-
Exploring the Immune System’s and Silybin’s Impact on Cancer Cachexia
Cancer cachexia is a complex syndrome that is characterized by the unintentional loss of body weight with or without fat loss. During cancer cachexia, there is an increase in inflammation consistent with various inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), Interleukin-1 beta …
-
Multimodal AI-Driven Biomarker for Early Detection of Cancer Cachexia
Cancer cachexia is a metabolic syndrome characterized by substantial skeletal muscle loss, impacting cancer patients' survival and quality of life. Despite its clinical significance, early detection remains a challenge due to the lack of standardized diagnostic criteria and the reliance on indirect …
-
Identifying Cancer Cachexia Factors Affecting Muscle Stem Cell Regeneration Capacity
À la demande de l'auteur, le résumé a été retiré en raison de la nature confidentielle de la thèse. Il sera ajouté une fois la période d'embargo terminée. At the author’s request, the abstract has been removed due to the confidential nature of the thesis. It will be added once the embargo period …
-
Small intestinal protein metabolism during cancer cachexia and chemotherapy in mice
Cachexia is the leading cause of morbidity and mortality in patients with cancer. Mechanisms The effects of cancer cachexia and chemotherapy on small intestinal protein metabolism and the mechanisms regulating recovery are currently not known. Compromises to small intestinal protein metabolism may …
Page 1 of 7